ALLOS

AcronymDefinition
ALLOSAlliance Operating System
References in periodicals archive ?
The deal was finalised through a short-form merger carried out on 5 September, after Spectrum secured 89.98% in Allos via its USD1.82 (EUR1.44) a share tender offer completed on 4 September, the buyer said.
Biotechnology company Spectrum Pharmaceuticals Inc (NasdaqGS:SPPI) said on Friday that it has extended its tender offer period to purchase all of the outstanding common shares of Allos Therapeutics Inc (NasdaqGS:ALTH) for USD1.82 per share in cash, without interest and less any applicable withholding taxes.
Spectrum Pharmaceuticals Inc (NasdaqGS:SPPI) (Spectrum) and Allos Therapeutics Inc (NasdaqGS:ALTH) (Allos) on Thursday announced that, on 9 May 2012, each had received from the Federal Trade Commission (FTC) a Request for Additional Information and Documentary Material (Second Request) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to the acquisition of Allos by Spectrum.
Allos has two product candidates in late-stage clinical development: EFAPROXYN (efaproxiral), a radiation sensitizer currently under evaluation in a pivotal Phase 3 trial in women with brain metastases originating from breast cancer, and PDX (pralatrexate), a novel, next-generation antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma.
Spectruma[euro](tm)s USD1.82 (EUR1.45) a share tender offer for Allos, launched on 13 April following the signing of an agreement on 4 April, is scheduled to expire on 4 September after having been extended a few times.It needs to win the acceptance of Allos shareholders controlling a majority of the firma[euro](tm)s shares, among other conditions, the two companies said.
Biotechnology company Spectrum Pharmaceuticals Inc (NasdaqGS:SPPI) revealed on Friday the extension of its tender offer period to purchase all of the outstanding shares of common stock of Allos Therapeutics Inc (NasdaqGS :ALTH) for USD1.82 per share in cash, without interest and less any applicable withholding taxes.
Under the definitive agreement Spectrum is expected to acquire all of the outstanding shares of Allos for USD1.82 per share in cash and one Contingent Value Right (CVR).
Biotechnology company Spectrum Pharmaceuticals Inc (Nasdaq:SPPI) and Allos Therapeutics Inc (Nasdaq:ALTH), a biopharmaceutical company, announced today that Spectrum has provided an additional extension of the offer period in connection with its tender offer to purchase all of the outstanding shares of common stock of Allos.
In early April, the parties announced they had agreed for Spectrum to acquire Allos via a tender offer at USD1.82 (EUR1.41) a share in cash plus one contingent value right (CVR) for additional USD0.11 a share based on certain milestones.
Allos looks forward to working closely with its partner Mundipharma and the CHMP during the re-examination process, said Charles Morris, Allos' chief medical officer.